MedTrace Logo

The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

NCT03460808 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2018-03-09

No results posted yet for this study

Summary

Single-arm, open-lable, multicentre study to compare the efficacy and safety of atorvastatin, acetylcysteine plus danazol with danazol monotherapy in patients with corticosteroidresistant/relapsed ITP.

Conditions

Interventions

DRUG

atorvastatin

Atorvastatin was used in combination with acetylcysteine and danazol.

DRUG

Acetylcysteine

Acetylcysteine was used in combination with atorvastatin and danazol.

DRUG

Danazol

Danazol was used in combination with atorvastatin and acetylcysteine or as the monotherapy

Sponsors & Collaborators

  • Peking University People's Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-10
Primary Completion
2020-01-01
Completion
2023-01-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03460808 on ClinicalTrials.gov